This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Health Winners & Losers

Biotech news was thin, and health indices were flat midweek despite a halted clinical program and a few stock offerings and business deals. Immtech Pharmaceuticals' (IMM) stock took a beating Wednesday after the company announced the Food and Drug Administration put a clinical hold on its development program for pafuramidine, an experimental treatment in late-stage studies for Pneumocystis pneumonia and African sleeping sickness.

The company said preliminary findings from a safety study revealed abnormal laboratory values in several volunteers following treatment with the drug, and patients are now being closely monitored for liver values. Shares fell $2.90, or 49.6%, to $2.95.

Headed slightly in the other direction, Cubist Pharmaceuticals (CBST) said Wednesday that it would buy Illumigen Biosciences for $9 million in cash. Cubist expects to file an IND for Illumigen's lead candidate, a Hepatitis C Virus (HCV) treatment, in 2008. Ilumigen will become a wholly owned subsidiary of Cubist, and Cubist will pay Illumigen up to $75.5 million during the development of the HCV treatment.

If Cubist develops Illumigen products for things other than HCV, the companies said development and regulatory milestone payments could amount to $117 million. And if any Illumigen product is commercialized, Cubist could pay an additional $140 million in milestone payments.

Cubist shares were trading down 48 cents, or 2.2%, at $21.77. The stock is a component of the Nasdaq biotechnology index, which was up 4.01, or 0.5%, at 863.99.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
NGSX $0.01 38.89%
CBST $101.94 0.14%
DYAX $26.06 -2.00%
IDRA $3.01 -1.30%
AAPL $131.05 -1.20%


DOW 18,020.25 -17.72 -0.10%
S&P 500 2,105.03 -3.89 -0.18%
NASDAQ 5,042.1130 -18.1330 -0.36%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs